Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Novo Nordisk A/S — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 23.3× Norwegian Cruise Line Holdings Ltd's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and Novo Nordisk A/S for 116 Days on average.
| NCLH | NVO | |
|---|---|---|
Market Cap | $7.11B | $165.31B |
Volume | 22,683,268 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $63.98 |
52-Week Low | $14.12 | $35.29 |
Typical Hold Time | 68 Days | 116 Days |
Enterprise Value | $21.93B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company shows strong profitability with a 7.49% net income margin and attractive valuation metrics, including a P/E of 9.39. Recent news highlights management's focus on booking strategies and debt management, with a $950 million senior notes offering priced in September 2026. Analyst consensus is positive, with a $20.86 price target implying significant upside from current levels.
The outlook for NCLH is cautiously optimistic, supported by earnings strength and analyst buy ratings, but risks include high debt levels and yield pressure. Investment opportunity lies in valuation discount and operational improvements, though investors must monitor competitive dynamics and macroeconomic sensitivity. The stock's trajectory hinges on sustained demand and effective capital allocation.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
